Take action seeks European MHRA clearance to initiate hESC derived RPE cell Phase 1/2 study in SMD Advanced Cellular Technology, Inc silagratablets.net . , a leader in the field of regenerative medicine, announced today that it offers filed a scientific trial application with the European Medications and Healthcare items Regulatory Agency searching for clearance to initiate its Phase 1/2 medical trial using retinal pigment epithelial cells derived from human embryonic stem cells to treat patients with Stargardt’s Macular Dystrophy .’ Related StoriesHPV analysis partnership signed between Beckman Coulter and IncellDxImproved results yielded from new ChIP-seq protocolInner ear harm brain warnings from nerve cellsThe proposed scientific trial will be a prospective, open-label research that is made to determine the basic safety and tolerability of the RPE cells pursuing sub-retinal transplantation to individuals with advanced SMD, like the FDA-cleared U.S.
Related StoriesResearchers find that stem cell treatment may reduce cognitive impairment related to dementia with Lewy bodiesStem cell study to greatly help fight congenital brittle bone diseasePublic plan needed to decrease stem cell tourism, state experts We are able to generate a practically unlimited supply of healthy RPE cells, said Robert Lanza, MD, ACT’s Chief Scientific Officer. In our animal research, we noticed significant improvement in visual performance over untreated animals, and did not find any adverse effects of the injection of RPE cells. In extending our studies to human patients, it really is our hope that we will present that the injected RPE cells will rescue photoreceptors and slow, if not stop, the progression of macular degeneration.on November 22 , ACT announced that it got received FDA approval to begin with treating patients as part of the company’s Stage I/II Clinical Trial deal with Stargardt’s Disease, a kind of juvenile macular degeneration.